259 related articles for article (PubMed ID: 8374869)
1. Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study.
Punt CJ; Burghouts JT; Croles JJ; van Liessum PA; de Mulder PH; Kamm Y
Cancer; 1993 Oct; 72(7):2107-11. PubMed ID: 8374869
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
[TBL] [Abstract][Full Text] [Related]
3. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Tournigand C; Louvet C; de Gramont A; Lucchi E; Seitz JF; Mal F; Raymond E; Cady J; Carola E; Krulik M
Cancer; 1997 Mar; 79(6):1094-9. PubMed ID: 9070485
[TBL] [Abstract][Full Text] [Related]
4. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ
J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
Patt YZ; Hoque A; Lozano R; Pozdur R; Chase J; Carrasco H; Chuang V; Delpassand ES; Ellis L; Curley S; Roh M; Jones DV
J Clin Oncol; 1997 Apr; 15(4):1432-8. PubMed ID: 9193336
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Lenk H; Wiener N; Boese-Landgraf J; Schalhorn A
Semin Oncol; 1992 Apr; 19(2 Suppl 4):57-62. PubMed ID: 1553576
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).
Köhne CH; Wilke H; Hecker H; Schöffski P; Käufer C; Rauschecker H; Andreesen R; Ohl U; Lange HJ; Klaassen U
Ann Oncol; 1995 May; 6(5):461-6. PubMed ID: 7669711
[TBL] [Abstract][Full Text] [Related]
8. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study.
Hegewisch-Becker S; Gruber Y; Corovic A; Pichlmeier U; Atanackovic D; Nierhaus A; Hossfeld DK
Ann Oncol; 2002 Aug; 13(8):1197-204. PubMed ID: 12181242
[TBL] [Abstract][Full Text] [Related]
9. Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
Aranda E; Cervantes A; Carrato A; Fernández-Martos C; Antón-Torres A; Massutí T; Barneto I; García-Conde J; Barón JM; Díaz-Rubio E
Ann Oncol; 1996 Aug; 7(6):581-5. PubMed ID: 8879371
[TBL] [Abstract][Full Text] [Related]
10. Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.
Steger GG; Mader RM; Djavanmard MP; Gnant MF; Locker G; Marosi C; Rainer H; Jakesz R
J Cancer Res Clin Oncol; 1994; 120(5):314-8. PubMed ID: 8126062
[TBL] [Abstract][Full Text] [Related]
11. Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.
Hausmaninger H; Moser R; Samonigg H; Mlineritsch B; Schmidt H; Pecherstorfer M; Fridrik M; Kopf C; Nitsche D; Kaider A; Ludwig H
Eur J Cancer; 1999 Mar; 35(3):380-5. PubMed ID: 10448286
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
de Gramont A; Bosset JF; Milan C; Rougier P; Bouché O; Etienne PL; Morvan F; Louvet C; Guillot T; François E; Bedenne L
J Clin Oncol; 1997 Feb; 15(2):808-15. PubMed ID: 9053508
[TBL] [Abstract][Full Text] [Related]
13. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Knauf WU; Boese-Landgraf J; Schalhorn A; Zeitz M
Semin Oncol; 1992 Apr; 19(2 Suppl 3):197-203. PubMed ID: 1557647
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council.
Seymour MT; Slevin ML; Kerr DJ; Cunningham D; James RD; Ledermann JA; Perren TJ; McAdam WA; Harper PG; Neoptolemos JP; Nicholson M; Duffy AM; Stephens RJ; Stenning SP; Taylor I
J Clin Oncol; 1996 Aug; 14(8):2280-8. PubMed ID: 8708718
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
Aranda E; Cervantes A; Dorta J; Blanco E; Fernández-Martos C; Cruz-Hernandez JJ; Carrato A; Gonzalez-Mancha R; García-Conde J; Díaz-Rubio E
Cancer; 1995 Aug; 76(4):559-63. PubMed ID: 8625147
[TBL] [Abstract][Full Text] [Related]
17. Activity of high dose 24 hour 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer.
Nobile MT; Barzacch MC; Sanguineti O; Chiara S; Gozza A; Vincenti M; Lavarello A; Cognein P; Lionetto R; Percivale PL; Bertoglio S; Murolo C; Esposito M; Vannozzi MO; Rosso R
Anticancer Res; 1998; 18(1B):517-21. PubMed ID: 9568171
[TBL] [Abstract][Full Text] [Related]
18. 5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration.
Buter J; Sinnige HA; Sleijfer DT; de Vries EG; Willemse PH; van der Graaf WT; Verschueren RC; Mulder NH
Cancer; 1995 Mar; 75(5):1072-6. PubMed ID: 7850703
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
[TBL] [Abstract][Full Text] [Related]
20. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Beerblock K; Rinaldi Y; André T; Louvet C; Raymond E; Tournigand C; Carola E; Favre R; de Gramont A; Krulik M
Cancer; 1997 Mar; 79(6):1100-5. PubMed ID: 9070486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
